Vaccines Still Matter – Global Healthy Living Foundation Sees Strong Patient Engagement Despite Current Negative Rhetoric
...Surprising uptake among chronically ill patients, despite continuing anti-vaccine rhetoric from many media, individuals and government sources.
GHLF's coverage of the World Vaccine Congress, held in Washington, D.C. last week, reached more than 23,000 non-attendees and generated more than 800 engagements across platforms including LinkedIn, X, Instagram, Facebook, TikTok, and YouTube. A special video podcast episode of Healthcare Matters recorded at the conference and published on April 25 has so far garnered more than 4,900 views/listens and continues to climb.
'These aren't big numbers for consumer-oriented social media posts or podcasts,' said Robert Popovian, PharmD, MS, GHLF's Chief Science Policy Officer.
'But GHLF's digital output is organic, high-credibility and tailored to niche audiences of professionals, as well as individuals and caregivers with specific chronic diseases. It isn't necessarily relevant unless you have, or care for someone, with a very specific disease, so these are significant numbers in a short time frame,' he said.
'It signals to us that maintaining and protecting health in the face of a chronic illness is important to this audience. They want information about vaccines, and they understand the value of vaccinations in reaching their health goals,' Dr. Popovian added.
'Before the current drop in vaccination rates among the general public in some areas of the U.S., people with ongoing illnesses who were often immunocompromised, could rely on the overall community immunity to add an extra measure of protection against disease. This extra protection, afforded by healthy vaccinated individuals who felt a responsibility to their neighbors, isn't as prevalent today so we lose community immunity and diseases that were eradicated in the U.S. many years ago are returning,' Popovian added.
'What really struck me at the World Vaccine Congress was how aligned people were — from pharma leaders to advocates to policy folks — about the urgency of fighting misinformation and navigating funding shortfalls. Even with different perspectives, there was a real sense of unity and shared purpose, which left me hopeful about the road ahead, especially with new applications for mRNA vaccines,' Ben Blanc, MS, GHLF's Director of Digital Production and Engagement said.
The Healthcare Matters podcast, which proved immediately popular among patients, was recorded live at the Congress and hosted by Dr. Popovian and Mr. Blanc. The episode featured vaccine experts, including:
Richard Hughes, Partner at Epstein Becker & Green and Lecturer in Law at George Washington University
Tommy Acciani, Director, U.S. Vaccine Policy, GSK
Abby Bownas, Co-lead, Adult Vaccine Access Coalition
Rekha Lakshmanan, Chief Strategic Officer, The Immunization Partnership
The podcast explored the current landscape of adult immunization policy, funding threats to vaccine infrastructure, misinformation challenges, and what's next for vaccine innovation.
For continued updates and to access GHLF's World Vaccine Congress content, visit: https://ghlf.org/vaccine-resources/
All interviews, as well as our special video episode, can be found here:
About GHLF
The Global Healthy Living Foundation is a U.S. based, 501(c)(3) nonprofit, international organization whose mission is to improve the quality of life for people with chronic illnesses by advocating for improved access to health care through education, patient-centered clinical research, support, advocacy, and economic and policy research. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the international, digital community for millions of people living with arthritis and their supporters worldwide who seek education, support, activism, and patient-centered research in English, Spanish, and French. In addition to arthritis and autoimmune disorders, GHLF supports dermatology, gastroenterology, neurology, cardiology, oncology, infectious disease, rare disease, and pulmonary patients through a host of different programs and activities which draw more than 700,000 patients a month to GHLF websites and create more than 10 million impressions a month on seven social media platforms. In 2024, GHLF had more than 1 million views and listens with its patient-centered audio-visual content, found on YouTube and podcast platforms. GHLF never asks the public for donations, receiving funding instead through governments, non-governmental organizations, foundations, industry, family foundations, and GHLF Co-Founder Louis Tharp. Visit www.ghlf.org for more information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. ('Kissei') to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies for the potential treatment of patients with thyroid eye disease (TED), and VRDN-003 is a potential best-in-class, subcutaneous, half-life extended anti-IGF-1R antibody with the same binding domain as veligrotug. TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye, often causing swelling, discomfort, and double vision, among other signs and symptoms. 'After running a very competitive partnering process, we are thrilled to partner with Kissei to bring these potential best-in-class medicines to TED patients in Japan,' said Steve Mahoney, Viridian's President and CEO. 'Kissei has an established strong track record of successfully developing and commercializing in-licensed, rare disease medicines. Kissei shares our enthusiasm and commitment to these programs, and we believe Kissei is an ideal partner for us in Japan. Both companies look forward to moving quickly to advance these novel treatment options for patients.' 'As we seek to further expand our pipeline in rare and intractable diseases, we are very excited by the potential of veligrotug and VRDN-003 to address the significant unmet needs of TED patients in Japan, based on veligrotug's strong and consistent phase 3 clinical data in THRIVE and THRIVE-2,' said Mutsuo Kanzawa, Chairman and CEO of Kissei. 'This collaboration reinforces our mission to contribute to the health of people around the world through innovative pharmaceutical products, and we are committed to bringing important treatment options to Japanese patients as rapidly as possible.' Under the terms of the agreement, Viridian will grant Kissei an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan. Viridian will receive an upfront cash payment of $70 million, with the potential to receive an additional $315 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales in Japan with percentages ranging from the 20s to mid-30s. Kissei will be responsible for all development, regulatory, and commercialization activities, and associated costs, in Japan. Renexes LLC served as an advisor to Viridian in connection with the transaction. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X. About Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy 'contributing to society through high-quality, innovative pharmaceutical products' and 'serving society through our employees.' As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei is engaged in bringing new drugs into the world through drug discovery and licensing activities in its focus fields of rare/intractable diseases, urology, and nephrology/dialysis. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, 'anticipate,' 'believe,' 'become,' 'continue,' 'could,' 'design,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'on track,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: Viridian's partnership with Kissei; Viridian's ability to achieve development, regulatory, and commercial milestone payments and receive royalties on the commercial sale of our product candidates pursuant to the agreement with Kissei; clinical development and anticipated commercialization of Viridian's product candidates, including veligrotug (formerly VRDN-001) and VRDN-003; the potential utility, efficacy, potency, safety, clinical benefits, clinical response, convenience, and number of indications of veligrotug and VRDN-003; Viridian's product candidates potentially being best-in-class; whether veligrotug and VRDN-003 will serve an unmet need; and Viridian's expectations regarding the potential commercialization of veligrotug and VRDN-003, if approved, including under the agreement with Kissei. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian's product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; expectations and changes regarding the timing for regulatory filings; regulatory interactions; uncertainty and potential delays related to clinical drug development; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; competition from other therapies or products; estimates of market size; our future operating results and financial performance; Viridian's intellectual property position; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the 'Risk Factors' section of our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.
Business Wire
2 hours ago
- Business Wire
Veolia Heads a Groundbreaking Wastewater Epidemiological Surveillance Across Europe
PARIS--(BUSINESS WIRE)--Regulatory News: Veolia (PARIS:VIE), the world leader in water technologies, is at the helm of a groundbreaking European epidemiological surveillance program that leverages wastewater as a real-time health indicator. The goal: detect emerging threats early and protect urban populations across the continent. Veolia will oversee the monitoring aspect of this three-year program and will analyze up to 500 wastewater samples collected from European cities in its laboratories in Spain. Each sample will undergo more than 500 in-depth analyses, targeting a wide range of pollutants, viruses, bacteria, and drug residues. This initiative is aligned with the revised European directive on wastewater treatment, which formally embeds epidemiological surveillance as a pillar of public health. It is also part of the European 'One Health' strategy, which will enable the analysis of collective behavior, the assessment of the impact of public policies, and the identification of new threats, while strengthening Europe's health sovereignty. This principle was recently reiterated in the European Strategy for Water Resilience. Estelle Brachlianoff, CEO of Veolia said: 'Being a pioneer means anticipating tomorrow's challenges, and that's exactly what we're doing here, by transforming wastewater into an early warning tool on a European scale. This project is a concrete embodiment of our GreenUp strategic plan: our environmental solutions are also solutions for the health of citizens and the resilience of European territories. We are delighted to be able to bring the Group's expertise in water treatment and environmental health to the European Union, and to pave the way for a more connected, intelligent, and preventive public health system.' The project is led by Veolia, in partnership with the CSIC (Spanish National Research Council), Cetaqua (Veolia Water Technology Center), and the University of Santiago de Compostela. It is based on more than ten years of field experience in wastewater monitoring in Madrid, Barcelona, and Seville, covering nearly a third of the Spanish population. Daniel Tugues, CEO of Veolia Spain, said: 'The Covid-19 pandemic has revealed the untapped potential of wastewater for public health monitoring. This project puts that learning into practice on a large scale. We are very proud that the expertise of our teams is recognized at the European level. Thanks to this project, Spain is at the forefront of a new approach to environmental health, combining scientific rigor, technological innovation, and a commitment to the common good.' ABOUT VEOLIA Veolia group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tonnes of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024.
Yahoo
9 hours ago
- Yahoo
TransLogic™ Showcases Modernization Solutions at Healthcare Facilities Conference
Advanced transport automation enhances patient care and reduces operational costs BROOMFIELD, Colo., July 29, 2025--(BUSINESS WIRE)--TransLogic™, a Swisslog Healthcare company and a leading supplier in transport automation, will demonstrate how modernizing operational technology optimizes healthcare facility operations at the 2025 Health Care Facilities Innovation Conference. The event, July 27-30 in Columbus, Ohio, brings together over 3,000 healthcare facility professionals focused on advancing safety and innovation in the healthcare-built environment. TransLogic will exhibit at booth #906 in the Exhibition Hall, showcasing solutions that streamline internal logistics and boost operational performance through innovations in transport automation. The conference features over 70 speakers and thought leaders, along with 300 exhibitors presenting the latest technologies in healthcare facility management. Attendees can explore TransLogic's Design Assist offering and discuss modernizations that address IT security for pneumatic tube systems. The Design Assist approach brings transport automation experts into the early design phases of hospital construction projects, fostering collaboration that enhances efficiency and ensures long-term serviceability. Modernizations directly address security concerns by upgrading current versions of software & firmware, and installing the most updated hardware that provide robust IT security provisions. "As healthcare facilities face mounting pressure to maximize resources, our trusted operational technology addresses these challenges head-on," said Adam Tappen, Senior Vice President of Sales and Service at TransLogic North America. "Our pneumatic tube systems, proudly made in the USA, offer tangible benefits that facility managers can implement to transform their operations and enhance overall healthcare delivery through thorough early planning, consistent maintenance, and system updates." TransLogic will highlight the significant impact of its systems on healthcare operations. Company research shows that in a 300-bed hospital, a well-designed pneumatic tube system can save approximately $1.3 million annually in courier labor costs, with nurses spending 22% less time searching for missing medications. "The second half of 2025 promises exciting developments for healthcare facilities as we continue to advance visibility into hospital pneumatic tube systems," said Scott Fincher, Product Director, Transport Automation at TransLogic and Swisslog Healthcare. "We'll soon be able to introduce a solution that not only meets today's challenges but anticipates tomorrow's needs, especially in the day-to-day happenings with our facilities partners." For more information about TransLogic and its offerings, visit About Swisslog Healthcare Swisslog Healthcare provides pharmacy workflow automations through robotic solutions and operational technology that enable hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit About TransLogic™ TransLogic™, a Swisslog Healthcare Company, builds on its 100 years of operational technology expertise to reliably automate the delivery of critical items and leverage innovations which transcend industry standards in transport automation. TransLogic™ products are manufactured in the USA, resulting in nominal supply chain issues, fewer shipping delays, and quality controls which meet North America's standards. Learn more about TransLogic™ solutions at View source version on Contacts Media Contacts Erica Fetherston10 to 1 Public Relationserica@ (480) 676-9141 Emily Cardone10 to 1 Public Relationsemily@ (480) 245-3983 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
